BioMarin agreed to acquire Amicus Therapeutics for $4.8 billion, gaining two approved therapies for Pompe and Fabry diseases and a late-stage clinical asset. The companies said the purchased products generated nearly $450–600 million in recent revenue and provide BioMarin with immediate commercial scale in lysosomal disorders. Analysts cited the strategic logic: the acquisition combines BioMarin’s rare-disease commercialization infrastructure with Amicus’ marketed medicines and pipeline to accelerate revenue and R&D synergies. Deal terms include a 33% premium to Amicus’ recent share price; integration risks will center on manufacturing, post-merger pipeline prioritization and capturing projected growth for the acquired brands.